Abbott’s FreeStyle Libre glucose sensor has already been proven to help people with both Type 1 and Type 2 diabetes better manage their blood sugar levels, and a new study demonstrates just how ...

Abbott Laboratories ABT recently received the approval from Health Canada for its next-generation FreeStyle Libre 2 system for diabetics above the age of four. The regulatory approval makes the sensor ...

On social media, Tandem Diabetes Care (Nasdaq:TNDM) said the launch of a new integration for its insulin pump system is near.

(RTTNews) - Abbott Laboratories (ABT) Thursday announced positive data from REFLECT studies of its FreeStyle Libre continuous glucose monitoring (CGM) technology. The REFLECT studies, funded by Abbott ...

Though continuous glucose monitors have long been more widely used among people with Type 1 diabetes, new research has increasingly shown that the Type 2 population can majorly benefit from CGM use, ...

Abbott continues to get a boost in its Medical Devices business from its Diabetes unit's portfolio of continuous glucose ...

Correction: A previous version of this article failed to specify that the deal concerns Freestyle Libre Pro, rather than the consumer version, Freestyle Libre. Livongo Health, the digital chronic ...

Healthcare major Abbott has launched its next-generation continuous glucose monitoring (CGM) device, the FreeStyle Libre 2 Plus, in India, offering real-time glucose readings every minute and optional ...

The FDA granted clearance for a standalone reader to be used for glucose management with the FreeStyle Libre 3 CGM. Users will have the option to use either the reader or the device’s smartphone app.

Medicare is now covering continuous glucose monitoring (CGM) for all beneficiaries with diabetes who use insulin, as well as those with a "history of problematic hypoglycemia." The new policy decision ...